SEHK:6855Biotechs
Ascentage China IND Clearance Puts BTK Degrader On Global Cancer Track
Ascentage Pharma Group International (SEHK:6855) received investigational new drug clearance in China for APG-3288, its next generation BTK targeted protein degrader.
The Chinese clearance follows earlier U.S. FDA approval for clinical testing, aligning the program across two major drug development markets.
APG-3288 is being developed for treatment resistant blood cancers, with a focus on hematologic malignancies that do not respond to existing BTK therapies.
For investors tracking oncology...